BPC-157

BPC-157 is a synthetic pentadecapeptide studied in animal and laboratory models of tissue injury, inflammation and mucosal protection. Human evidence is small and heterogeneous, and preclinical findings cannot be presented as established treatment effects. FDA BPC-157 briefing

What human evidence exists

In its July 2026 assessment, FDA identified five distinct human study groups. Two older controlled groups are known through meeting abstracts: a placebo-controlled phase 1 tolerability/pharmacokinetic study in healthy volunteers (reported by Veljaca in both 2002 and 2003) and a randomized, double-blind, placebo-controlled ulcerative-colitis study reported by Ruenzi in 2005. The three later full primary publications are a retrospective knee chart review, an uncontrolled interstitial-cystitis pilot and a two-person intravenous safety pilot. This is a count of study groups, not a measure of proven benefit. FDA found the ulcerative-colitis abstract too incomplete to establish efficacy or safety and the human record insufficient for long-term safety conclusions. FDA BPC-157 briefing, pp. 26, 41–43, 53–54 · Knee report, PMID 34324435 · Interstitial-cystitis pilot, PMID 39325560 · IV pilot, PMID 40131143

A 2025 orthopaedic systematic review identified 36 studies in a search ending June 3, 2024: 35 preclinical and one clinical knee study, including 12 participants who received BPC-157 alone. That scoped search is not a census of all indications or the human literature through 2026. PMID 40756949 · Knee report, PMID 34324435

The 2025 IV pilot observed two previously exposed people around infusions. It cannot establish efficacy, general safety, pharmacokinetics or a validated formulation. The 2024 interstitial-cystitis pilot had 12 participants and no control group, so its reported symptom changes cannot establish a treatment effect. PMID 40131143 · PMID 39325560

A 2026 biopharmaceutical narrative review describes uncharacterized formulations, a pharmacokinetic–pharmacodynamic disconnect and no completed phase 2 trial in its assessment. FDA’s inventory nevertheless includes the 2005 phase 2 meeting abstract; the abstract does not establish efficacy or a completed, adequately reported development program. The overall evidence grade remains low because the human studies are small, heterogeneous and incompletely reported. PMID 42198317 · FDA BPC-157 briefing

Regulatory and quality boundaries

BPC-157 is not an FDA-approved drug. FDA lists BPC-157 among withdrawn bulk-drug nominations with potential immunogenicity, peptide-impurity and active-pharmaceutical-ingredient characterization risks, and says available safety information is insufficient for proposed compounded routes. Its July 2026 advisory materials evaluate possible inclusion on the 503A bulk-substances list; they are not a drug approval or final list determination. FDA compounding safety page · FDA BPC-157 briefing

Product labels, online seller descriptions and animal studies do not establish identity, sterility, dose accuracy or clinical benefit in humans. No regimen, purchasing advice or self-treatment instructions belong in this dossier. FDA BPC-157 briefing

Source-count basis (September 28, 2026): The badges count distinct works directly cited here, not every study covered by a review or FDA assessment. The seven works are the 2021 knee report, 2024 interstitial-cystitis pilot, 2025 IV pilot, 2025 orthopaedic review, 2026 biopharmaceutical review, FDA BPC-157 briefing and FDA compounding safety page. “Human” counts the three directly cited full primary human publications; the two abstract-only groups are represented by the FDA briefing and are not added as full publications. “Preclinical” counts directly cited primary experiments (none), not the 35 studies included in the orthopaedic review. “Open access” counts all seven works: both FDA documents and reviews have free full text, and the journal identifies all three human papers as open access. These source counts do not grade efficacy.

This dossier is a research summary, not medical advice or self-treatment guidance.